Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA) — PROSTIRNA

Prostatic Cancer, Castration-Resistant Clinical Trial

Official title:
Phase I Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer

Status Withdrawn

Clinical Trial Summary

This is a single site, open-label, non-randomized, dose escalation phase I study designed to evaluate the safety, the tolerability and the Recommended Phase II Dose (RP2D) of SXL01, a synthetic small interfering ribonucleic acid (RNA) targeting the androgen receptor messenger RNA (mRNA), in patients with metastatic castration-resistant prostate cancer. A standard method "3+3" will be used for dose escalation. A maximum of 30 patients will complete the dose-escalation phase of the study; 12 additional patients will be included at the RP2D in the expansion phase.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Prostatic Cancer, Castration-Resistant
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

Clinical Trial Details

NCT number	NCT02866916
Study type	Interventional
Source	Institut Claudius Regaud
Contact
Status	Withdrawn
Phase	Phase 1
Start date	September 2017
Completion date	June 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04381832` - Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT06276465` - Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging	Phase 3
Terminated	`NCT04157088` - Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)	Phase 2
Recruiting	`NCT04141709` - Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer	N/A